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The Journal of Immunology
Primary EBV Infection Induces an Acute Wave of Activated
Antigen-Specific Cytotoxic CD4+ T Cells
Benjamin J. Meckiff,* Kristin Ladell,† James E. McLaren,† Gordon B. Ryan,*
Alison M. Leese,* Eddie A. James,‡ David A. Price,† and Heather M. Long*
CD4+ T cells are essential for immune protection against viruses, yet their multiple roles remain ill-defined at the single-cell level
in humans. Using HLA class II tetramers, we studied the functional properties and clonotypic architecture of EBV-specific CD4+
T cells in patients with infectious mononucleosis, a symptomatic manifestation of primary EBV infection, and in long-term healthy
carriers of EBV. We found that primary infection elicited oligoclonal expansions of TH1-like EBV-specific CD4
+ T cells armed with
cytotoxic proteins that responded immediately ex vivo to challenge with EBV-infected B cells. Importantly, these acutely generated
cytotoxic CD4+ T cells were highly activated and transcriptionally distinct from classically described cytotoxic CD4+ memory
T cells that accumulate during other persistent viral infections, including CMVand HIV. In contrast, EBV-specific memory CD4+
T cells displayed increased cytokine polyfunctionality but lacked cytotoxic activity. These findings suggested an important effector
role for acutely generated cytotoxic CD4+ T cells that could potentially be harnessed to improve the efficacy of vaccines against
EBV. The Journal of Immunology, 2019, 203: 000–000.
E
fficient long-term control of persistent viral infection re-
quires the coordinated action of Ag-specific CD4+ and
CD8+ T cells (1). Upon Ag encounter, naive MHC class II
(MHCII)–restricted CD4+ T cells possess the ability to differen-
tiate into several distinct effector subsets, reflecting their various
helper roles in the immune response. After resolution of the initial
challenge, small populations of circulating Ag-specific CD4+ T cells
are retained as central memory T cells (TCM; CCR7
+CD45RA2) or
effector memory T cells (TEM; CCR7
2CD45RA2) (2). As a conse-
quence, the total CD4+ T cell pool is functionally and phenotypically
heterogeneous (3). However, at the Ag-specific level, virus-induced
CD4+ T cell responses are substantially less well defined in humans.
Little is known of the clonal composition or functional diversity
within individual epitope-specific populations or how virus-specific
CD4+ T cell responses evolve from primary to persistent viral
infection (4, 5).
In addition to their helper roles, it is now appreciated that some
CD4+ T cells can acquire perforin (Perf)/granzyme B (GzmB)–
mediated cytotoxic function, akin to CD8+ T cells (6). The ability
of cytotoxic CD4+ T cells (CD4-CTLs) to directly kill MHCII+
targets expressing cognate Ag in vitro has raised significant in-
terest among viral and tumor immunologists alike (7, 8). Such
functionality is particularly valuable for viral infections or cancers
occurring in cell lineages that either naturally express MHCII, or
can be induced to express MHCII, for example, following infec-
tion or transformation. In vivo, CD4-CTLs have been predomi-
nantly reported in humans in the context of persistent viral
infections, including CMV and HIV (8, 9), and various cancers
(7, 10). These collective observations suggested a key role for
chronic Ag exposure and progressive differentiation in the ac-
quisition of cytotoxic activity by CD4-CTLs, which often display
a late differentiated terminal effector memory T cell (TEMRA;
CCR72CD45RA2). Rare indications of CD4-CTLs in more acute
settings or following vaccination exist, but the relevance of these
observations remains unclear (11, 12). Induction of CD4-CTLs is
now considered an important goal in the design of many next-
generation vaccines (4, 13); however, greater definition of natu-
rally protective CD4+ T cells at the Ag-specific and single-cell
level is first required. To date, a lack of known epitopes and as-
sociated reagents for the ex vivo detection of Ag-specific CD4+
T cells has limited functional and clonotypic studies almost ex-
clusively to analyses of the entire CD4+ T cell pool or peptide-
stimulated CD4+ T cell populations, mostly following in vitro
culture (14–19).
In this study, we focus on EBV, an orally transmitted herpesvirus
that establishes lifelong infection of the memory B cell pool (20).
Primary EBV infection is often asymptomatic, but some individ-
uals present clinically with infectious mononucleosis (IM). Early
diagnosis is facilitated in these cases and provides a unique op-
portunity to study the evolution of immune responses to viral
infection in humans (21). In a previous study, we optimized EBV
peptide-MHCII (pMHCII) tetramer analysis to facilitate ex vivo
detection of EBV epitope-specific CD4+ T cell populations and
*Institute of Immunology and Immunotherapy, University of Birmingham, Edgbaston,
Birmingham B15 2TT, United Kingdom; †Division of Infection and Immunity, Cardiff
University School of Medicine, Cardiff CF14 4XN, United Kingdom; and
‡Tetramer Core Laboratory, Diabetes Program, Benaroya Research Institute at
Virginia Mason, Seattle, WA 98101
ORCIDs: 0000-0002-9856-2938 (K.L.); 0000-0002-7021-5934 (J.E.M.); 0000-0002-
7217-5729 (E.A.J.); 0000-0001-9416-2737 (D.A.P.); 0000-0003-2139-8292 (H.M.L.).
Received for publication April 1, 2019. Accepted for publication June 20, 2019.
This work was supported by Bloodwise UK (Project Grant 15021). D.A.P. is a
Wellcome Trust Senior Investigator (Award 100326Z/12/Z).
B.J.M. performed laboratory work, interpreted the data, and wrote the manuscript;
K.L. and J.E.M. performed laboratory work, interpreted the data, and edited the
manuscript; G.B.R. and A.M.L. performed laboratory work; E.A.J. contributed es-
sential reagents; D.A.P. oversaw the research, interpreted the data, and edited the
manuscript; H.M.L. designed and oversaw the research, interpreted the data, and
wrote the manuscript.
Address correspondence and reprint requests to Dr. Heather M. Long, Institute
of Immunology and Immunotherapy, University of Birmingham, Edgbaston,
Birmingham B15 2TT, U.K. E-mail address: h.m.long@bham.ac.uk
The online version of this article contains supplemental material.
Abbreviations used in this article: CD4-CTL, cytotoxic CD4+ T cell; GzmB, granzyme
B; IM, infectious mononucleosis; LCL, lymphoblastoid cell line; MHCII, MHC class II;
Perf, perforin; pMHCI, peptide–MHC class I; pMHCII, peptide-MHCII; TCM, central
memory T cell; TEM, effector memory T cell; TEMRA, terminal effector memory T cell.
This article is distributed under the terms of the CC BY 4.0 Unported license.
Copyright  2019 The Authors
www.jimmunol.org/cgi/doi/10.4049/jimmunol.1900377
 Published July 15, 2019, doi:10.4049/jimmunol.1900377









demonstrated that primary infection elicits high frequencies of
virus-specific CD4+ T cells against a broad range of Ags (22). These
initial expansions are rapidly culled to leave small populations of
TCM and TEM CD4
+ T cells that persist throughout the chronic
phase of infection. Importantly, EBV-infected memory B cells
uniformly express MHCII (20), and several groups have shown
that in vitro–isolated EBV-specific CD4+ T cells can recognize and,
in some cases, kill virus-transformed B cells (23–29). If also true
in vivo, such functionality would be highly advantageous against
EBV infection and associated diseases.
In this study, we used pMHCII tetramers to dissect the functional
and clonotypic properties of EBV-specific CD4+ T cells. We
showed that primary EBV infection elicits oligoclonal populations
of highly activated and cytotoxic EBV-specific CD4+ T cells,
which responded directly ex vivo to EBV-transformed B cells.
These acutely generated CD4-CTLs differed transcriptionally
from classically defined CD4-CTLs and waned through conva-
lescence to almost undetectable frequencies in the long-term Ag-
specific memory pool. Our findings provided valuable insights into
human CD4+ T cell immunity against EBV infection, with potential
implications for the rational design of vaccines against EBV.
Materials and Methods
Donors and ethics
The study cohort included 14 healthy carriers and 16 patients with acute
IM. All donors provided written informed consent in accordance with the
Declaration of Helsinki. Convalescence was defined temporally as 6 mo
after the initial diagnosis of IM. Study approval was granted by the South
Birmingham Local Research Ethics Committee (14/WM/1254).
Samples
PBMCs were separated via Ficoll-Hypaque centrifugation into RPMI 1640
medium (Sigma-Aldrich) supplemented with 8% FCS, 100 IU/ml penicillin,
100 mg/ml streptomycin, and 2 mM L-glutamine (R8). CD8+ T cells were
depleted using anti-CD8 Dynabeads (Life Technologies), and CD4+ T cells
were enriched using a Human CD4+ T Cell Enrichment Kit (STEMCELL
Technologies). Unless indicated otherwise, all experiments were per-
formed using enriched populations of CD4+ T cells with purities .95%.
Flow cytometry
Total or CD8-depleted PBMCs from healthy carriers or CD4-enriched
PBMCs from patients with IM were stained with optimized concentra-
tions of peptide–MHC class I (pMHCI) (University of Birmingham) or
pMHCII tetramers (Tetramer Core Laboratory of the Benaroya Research
Institute) containing epitopes from EBV or influenza virus (influenza A/
New York/348/03 H1N1) appropriate for the HLA type of each donor
(Table I). Cells were washed in PBS prior to pMHCI tetramer staining for
30 min or in human serum prior to pMHCII tetramer staining for 1 h. After
incubation, cells were washed in PBS, and nonviable events were labeled
using a LIVE/DEAD Fixable Dead Cell Stain Kit (eBioscience or Thermo
Fisher Scientific). Surface markers were identified using the following
directly conjugated Abs: anti-CD3 (SK7), anti-CD4 (RPA-T4), anti-CD14
(HCD14), anti-CD19 (HIB19), anti-CD38 (HIT2), anti-CD69 (FN50),
anti-CCR5 (J418F1), and anti-NKG2D (1D11) (BioLegend); anti-CD8
(RPA-T8), anti-CD14 (HCD14), anti-CD19 (HIB19), anti-CD107a
(H4A3), anti-CCR7 (3D12), and anti-CX3CR1 (2A9-1) (BD Biosci-
ences); and anti-CD45RA (2H4LDH11LDB9) (Beckman Coulter). For
detection of effector molecules, cells were fixed/permeabilized using
paraformaldehyde/saponin and stained with the following directly conju-
gated Abs: anti–GM-CSF (BVD2-21C11), anti-GzmB (GB11), anti–IFN-g
(4SB3), anti–IL-2 (MQ1-17H12), anti–IL-4 (8D4-8), anti–IL-10 (JES3-
9D7), anti–IL-21 (3A3-N2), and anti–TNF-a (Mab11) (BioLegend); and
anti-Perf (dg9) (eBioscience). For detection of transcription factors, cells
were fixed/permeabilized using a Transcription Factor Staining Buffer Set
(eBioscience) and stained with the following directly conjugated Abs:
anti–T-bet (4B10), anti-FOXP3 (236A/E7), and anti-Eomes (WD1928)
(eBioscience); and anti-Gata3 (L50-823) and anti-Hobit (Sanquin-Hobit/1)
(BD Biosciences). All Ab reagents were pretitrated for optimal perfor-
mance. Data were acquired using an LSR II or a Fortessa flow cytometer
(BD Biosciences) and processed using Kaluza Analysis Software
(Beckman Coulter).
Cell stimulation and functional profiles
CD8-depleted PBMCs from DR7+ healthy carriers were stimulated with
the EBNA2276–295 peptide at a concentration 0.005 mg/ml for 4 h in the
presence of brefeldin A (BD Biosciences). EBV-transformed autologous B
lymphoblastoid cell lines (LCLs) were generated as described previously
(30). Bulk PBMCs from healthy carriers or patients with IM were stimu-
lated with autologous LCLs at a ratio of 1:1 for 16 h in the presence of
brefeldin A, monensin, and anti–CD107a-FITC (H4A3) (BD Biosciences).
Stimulated cells were washed twice in R8 and processed as described
above prior to flow cytometric analysis of CD107a, IFN-g, IL-2, and TNF-a.
TCR repertoire analysis
Viable EBV-specific tetramer+ CD4+ T cell populations were sorted
at .98% purity directly into RNAlater (Thermo Fisher Scientific) using
a custom-modified FACSAria II flow cytometer equipped with DIVA
software version 8.0.1 (BD Biosciences). Unbiased amplification of all
expressed TRB gene rearrangements was conducted using a template-
switch–anchored RT-PCR with a 39 C region primer (31). Amplicons were
subcloned, sampled, sequenced, and analyzed as described previously (32).
Gene use was assigned using the International ImMunoGeneTics nomen-
clature (33). All functional TCR sequences were deposited online at
VDJdb (34). Expression of defined TCR Vb segments on the surface of
EBV-specific CD4+ T cells was assessed using a TCR Vb Repertoire Kit
(Beckman Coulter).
Statistics
Statistical comparisons were performed using the Mann–Whitney U test,
the Spearman rank test, or an unpaired Student t test with Welch correction
implemented via Prism 7 (GraphPad). The functional profiles of LCL-
responsive EBV-specific CD4+ T cells were compared using Funky Cells
and SPICE software version 5.32 (35).
Results
Ex vivo functional properties of EBV-specific memory
CD4+ T cells
To profile the functional capabilities of EBV-specific memory
CD4+ T cells in healthy virus carriers directly ex vivo, we
employed a panel of pMHCII tetramers (Table I) optimized in our
previous work (22). These reagents were used in conjunction with
intracellular flow cytometry to assess cytokine production in EBV-
specific CD4+ T cells following cognate peptide stimulation. The
gating strategy for data analysis (Supplemental Fig. 1) was con-
sistent with the recommendations of the Cancer Immunotherapy
Consortium (36). Careful experimental optimization was per-
formed to maintain sufficient TCR expression on the surface of
peptide-responsive CD4+ T cells to allow subsequent staining with
relevant pMHCII tetramers (Fig. 1A). As illustrated for a repre-
sentative healthy carrier, the majority of HLA DRB1*07:01
(DR7)–restricted EBNA2276–295–specific CD4
+ T cells produced
the effector cytokines IFN-g, TNF-a, and IL-2 (Fig. 1B). How-
ever, 21.4% of pMHCII tetramer+ cells made none of these cy-
tokines, most likely reflecting those residing in the TCM
component, which is less responsive ex vivo (2, 16, 22). Inter-
estingly, TNF-a was the most predominantly produced cytokine in
healthy carriers, made in isolation by 11.9% and in total by 78.6%
of DR7/EBNA2276–295–specific CD4
+ T cells. All IFN-g+ and/or
IL-2+ cells simultaneously produced TNF-a. There was no de-
tectable production of IL-4, IL-10, IL-21, or GM-CSF among
DR7/EBNA2276–295–specific CD4
+ T cells (data not shown and
Fig. 1B). In line with these findings, the transcription factor T-bet
was expressed in the vast majority of DR7/EBNA2276–295–specific
CD4+ T cells (mean 72.4%, n = 17) (Fig. 1C). Accordingly, EBV-
specific CD4+ T cells in healthy carriers displayed a TH1-like
response to Ag encounter directly ex vivo, consistent with a typ-
ical distribution of TEM and TCM memory phenotypes (22).
In further experiments, we tested the ability of EBV-specific
memory CD4+ T cells to directly recognize virus-infected cells
ex vivo, an observation previously limited to cultured cells in the
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in vitro setting (23–29). As shown for the representative healthy
carrier in Fig. 1D (and in the concatenated data from all donors in
Fig. 2D) low frequencies of CD4+ T cells produced effector cy-
tokines after overnight stimulation of PBMCs with autologous
EBV-transformed B LCLs. These responses were similarly TH1
polarized; however, higher proportions of LCL-stimulated CD4+
T cells produced IFN-g, TNF-a, or IL-2 in isolation compared
with peptide-stimulated CD4+ T cells. This may reflect lower
epitope densities in the context of natural Ag presentation or
functional heterogeneity among different populations of epitope-
specific CD4+ T cells. Small fractions of CD4+ T cells also
mobilized CD107a, indicating degranulation following LCL
stimulation (Fig. 1E).
Expansion of polyfunctional EBV-specific CD4+ T cells during
primary EBV infection
We next used pMHCII tetramers to investigate the functional
profile of EBV-specific CD4+ T cells induced by primary infection,
in which we have previously shown expansions of effector CD4+
T cells (CD45RA+, CCR72, CD62L2) specific for a broad range
of EBV Ags, with frequencies up to 10-fold greater than those
detected in healthy carriers (22). In line with these earlier findings,
the present cohort of patients with acute IM similarly had higher
frequencies of EBV-specific CD4+ T cells (Fig. 2A), and the
majority of these cells expressed the activation marker CD38
(CD38hi) (Fig. 2B). Moreover, T-bet expression was almost uni-
versal among EBV-specific CD4+ T cells in the setting of IM
(mean 98.5%), significantly exceeding T-bet expression frequen-
cies among total CD4+ T cells in the same donors (mean 26.0%,
p , 0.001; Fig. 2C) and EBV-specific memory CD4+ T cells in
healthy carriers (mean 72.4%, p , 0.001; Fig. 1C). Interestingly,
FOXP3 expression was almost undetectable among EBV-specific
CD4+ T cells in donors with either acute (Fig. 2C) or persistent
infection (Fig. 1C).
In light of these findings, we hypothesized that EBV-specific
CD4+ T cells in patients with IM might respond more efficiently
ex vivo to cognate Ag encounter. Accordingly, substantially higher
frequencies of responsive CD4+ T cells were detected in patients
with IM compared with healthy carriers after overnight stimula-
tion of PBMCs with autologous LCL (Fig. 2D). Furthermore, the
responding CD4+ T cells had different functional profiles at the
two stages of infection. In acute IM, smaller fractions of CD4+
T cells were polyfunctional (IFN-g+, TNF-a+, IL-2+) than in
healthy carriers (mean 6.5% versus mean 23.2%, respectively,
p , 0.05; Fig. 2E), in part reflecting more frequent production of
IL-2 during persistent infection (Fig. 2E). In addition, IFN-g was
the dominant cytokine produced by responsive CD4+ T cells
in patients with IM (mean 81.9% for IFN-g versus mean 54.0%
for TNF-a, p , 0.05; Fig. 2E), whereas TNF-a was the dom-
inant cytokine produced by responsive CD4+ T cells in healthy
carriers (mean 75% for TNF-a versus mean 64.8% for IFN-g;
Fig. 2E). Moreover, higher frequencies of LCL-stimulated
CD4+ T cells mobilized CD107a in patients with IM compared
with healthy carriers (mean 2.6% versus mean ,0.5%, respec-
tively, p , 0.0001; Fig. 2E), indicating higher levels of degran-
ulation in response to EBV-infected B cells in acute infection.
Interestingly, in acute infection, degranulation generally occurred
without coincident detectable production of IL-2.
Expression of cytotoxic proteins in EBV-specific CD4+ T cells
Degranulation is necessary but not sufficient for cytotoxic activity.
Therefore, to further investigate cytotoxic function, we assessed
the expression of Perf and GzmB in pMHCII tetramer+ CD4+
T cells directly ex vivo without prior in vitro stimulation. To
calibrate our measurements, we analyzed an EBV-specific memory
CD8+ T response against the HLA-A*02:01 (A2)–restricted epitope
BMLF1259–267, which is known to express Perf and GzmB
in vivo (37). As expected, Perf/GzmB were expressed by 36.5%
of all CD8+ T cells (Supplemental Fig. 2a) and 69.9% of
A2/BMLF1259–267–specific CD8
+ T cells in a representative healthy
carrier (Supplemental Fig. 2b). In contrast, relatively low percentages
of total CD4+ T cells (typically ,5%) expressed Perf/GzmB
in healthy carriers (Fig. 3A, 3G), and this was similarly the case
for the EBV-specific memory CD4+ T cells. In the example
healthy carrier shown, with a DR7/EBNA2276–295–specific
population comprising 0.03% of all CD4+ T cells, only 6.2% of
the tetramer+ cells expressed Perf/GzmB (Fig. 3B, left panels).
Interestingly, no Perf/GzmB+ events were detected in a coexistent
DR7-restricted memory CD4+ T cell population specific for the
influenza virus A matrix protein 1 epitope M143–59 (38) analyzed
at the same time point (Fig. 3B, right panels).
In contrast, Perf/GzmB were expressed by a greater frequency of
total CD4+ T cells in patients with IM compared with healthy
carriers (Fig. 3C, 3G). Furthermore, in the representative IM pa-
tient shown, in whom 0.77% of all CD4+ T cells were specific
for DR7/EBNA2276–295, a remarkable 76.9% of the pMHCII
tetramer+ cells expressed Perf/GzmB (Fig. 3D, left panels). In
contrast, no Perf/GzmB+ events were detected among a coexisting
influenza M143–59–specific CD4
+ T cells in this donor (Fig. 3D,
right panels), or any other patients with IM (n = 5), excluding the
possibility of bystander CD4+ T cell activation. Five of the pa-
tients with acute IM donated further blood samples 6 mo after the
initial diagnosis of IM, enabling analysis of Perf/GzmB expression
in EBV-specific CD4+ T cells during convalescence. Interestingly,
despite contraction of both the DR7/EBNA2276–295–specific CD4
+
T cell population (Fig. 3F, top plot) and Perf/GzmB expression in
the total CD4+ T cell pool (Fig. 3E) to frequencies typical of long-
term virus carriage (Fig. 3A, 3B), Perf/GzmB expression remained
elevated among the pMHCII tetramer+ cells (Fig. 3F, bottom plot).
The concatenated data for all patients with acute IM (n = 12),
patients with convalescent IM (n = 5), and healthy carriers (n = 15)
are shown in Fig. 3G. Perf/GzmB expression in EBV-specific CD4+
T cells was highest in patients with acute IM but was variable be-
tween donors (25.2–87.8%), likely reflecting differences in time
from symptomatic presentation to diagnosis (typically 10–21 d after
disease onset). However, in all cases, much higher frequencies of
Table I. pMHCI and pMHCII tetramers
MHC Class Pathogen Virus Phase Protein Coordinates Epitope MHC Restriction
MHCI EBV Lytic BMLF1 259–267 GLCTLVAML A2:01
MHCII EBV Latent EBNA1 (E1) 474–493 SNPKFENIAEGLRVLLARSH DRB5*01:01 (DR51)
MHCII EBV Latent EBNA2 (E2) 276–295 PRSPTVFYNIPPMPLPPSQL DRB1*07:01 (DR7)
MHCII EBV Latent EBNA2 (E2) 279–295 PRSPTVFYNIPPMPLPPSQL DRB3*02:02 (DR52b)
MHCII EBV Latent EBNA2 (E2) 301–320 PAQPPPGVINDQQLHHLPSG DRB1*03:01 (DR17)
MHCII EBV Lytic BMRF1 (BM) 136–150 VKLTMEYDDKVSKSH DRB1*03:01 (DR17)
MHCII EBV Lytic BaRF1 (Ba) 185–199 SRDELLHTRAASLLY DRB1*07:01 (DR7)
MHCII Influenza N/A Matrix protein 1 (M1) 43–59 MEWLKTRPILSPLTKGI DRB1*07:01 (DR7)
The Journal of Immunology 3









EBV-specific CD4+ T cells expressed Perf/GzmB in patients with
acute IM compared with healthy carriers (mean 56.2% versus
mean 2.7%, respectively, p , 0.0001). Notably, Perf/GzmB ex-
pression was also significantly raised among total CD4+ T cells
during acute infection (mean 15.5% for patients with IM versus
mean 1.2% for healthy carriers, p , 0.0001). This suggested that
the combined expansions of the broadly targeted EBV-specific
CD4+ T cell responses in acute IM were large enough to influ-
ence Perf/GzmB expression in the total CD4+ T cell pool. In the
patients with acute IM sampled again during convalescence, Perf/
GzmB expression frequencies in the total CD4+ T cell pool had
largely dropped to levels equivalent to those observed in healthy
carriers. However, expression of the cytotoxic proteins remained
at least partially elevated in some EBV-specific populations (mean
26.0% for patients with convalescent IM versus mean 2.7% for
healthy carriers, p , 0.001). Together, these data show that CD4-
CTLs are a major component of virus-specific CD4+ T cell
responses induced by primary EBV infection but not of those
maintained in long-term memory.
Expression of cytotoxicity-associated proteins in EBV-specific
CD4+ T cells
CD4-CTLs have to date been almost exclusively associated with
late differentiated TEMRA CD4
+ cells that accumulate during viral
persistence. In this context, several cellular markers have been
associated with the development or function of CD4-CTLs, in-
cluding the transcription factors Eomes (17, 39, 40) and Hobit
(11), the surface receptors NKG2D (41, 42) and CX3CR1 (17, 43),
and the class I–restricted T cell–associated molecule CRTAM
(44). We therefore asked whether these markers were similarly
expressed by the EBV-specific CD4-CTLs induced by acute in-
fection. Initial experiments assessed expression in total CD4+ and
pMHCII tetramer+ T cells. In a representative healthy carrier, each
marker was expressed by 1–5% of total CD4+ T cells, with the
FIGURE 1. EBV-specific memory CD4+ T cells are
polyfunctional. (A and B) CD4-enriched PBMCs from
a representative healthy carrier were either unmanip-
ulated or stimulated with EBNA2276–295 peptide,
stained with DR7/EBNA2276–295 tetramer, and ana-
lyzed by flow cytometry for intracellular expression of
IFN-g, TNF-a, and IL-2. (A) Representative DR7/
EBNA2276–295 tetramer staining of unmanipulated
(left panel) and peptide-stimulated PBMCs (right
panel). (B) Cytokine production in unmanipulated (left
column) and peptide-stimulated DR7/EBNA2276–295
tetramer+ CD4+ T cells (right column). (C) Summary
of transcription factor expression in unstimulated total
CD4+ (blue) and EBV-specific pMHCII tetramer+
CD4+ T cell populations (red) from healthy carriers
(T-bet, n = 17; GATA3, n = 13; FoxP3, n = 17). The
corresponding pMHCII tetramers are listed in Table I.
(D and E) PBMCs from healthy carriers were either
unmanipulated or stimulated with autologous LCLs
and analyzed by flow cytometry for intracellular ex-
pression of IFN-g, TNF-a, and IL-2 (D), and surface
mobilization of CD107a (E). Plots are gated on CD4+
T cells. Results are representative of at least three in-
dependent experiments with four donors. Error bars
indicate means 6 SD. Significance was determined by
unpaired Student t test with Welch correction (c).
***p , 0.001.
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exception of CRTAM (Fig. 4A). However, expression of all five
markers was negligible on memory EBV-specific tetramer+ CD4+
T cells in all healthy carriers (n = 15; data not shown). Substantially
higher frequencies of total CD4+ T cells expressed CX3CR1,
NKG2D, Hobit, and Eomes in a representative patient with IM
(Fig. 4B, top panels), and expression of CX3CR1, Hobit, and Eomes
was further increased among pMHCII tetramer+ CD4+ T cells in the
same donor (Fig. 4B, bottom panels). A similar pattern was ob-
served across all patients with acute IM (Fig. 4C, n = 6). Accord-
ingly, significantly higher expression of CX3CR1, Hobit, and Eomes
but not NKG2D or CRTAM, was detected among EBV-specific
CD4+ T cells compared with total CD4+ T cells (mean 62.0%
versus mean 9.4% for CX3CR1, respectively, p , 0.0001; mean
15.0% versus mean 4.6% for Hobit, respectively, p , 0.001; mean
56.4% versus mean 6.1% for Eomes, respectively, p , 0.001).
Subsequent analyses of CX3CR1, Hobit, and Eomes expression
among the Perf/GzmB+ and Perf/GzmB2 EBV-specific CD4+
T cells suggested that, during acute IM, EBV-specific CD4-CTLs
differ in their transcriptional program from classically reported
CD4-CTLs in other persistent viral infections. Thus, no single
marker was expressed by all Perf/GzmB+ EBV pMHCII tetramer+
CD4+ T cells, and CX3CR1 and Eomes were commonly expressed
by pMHCII tetramer+ CD4+ T cells lacking Perf/GzmB (Fig. 4D).
Furthermore, no combination of these markers was exclusively as-
sociated with cytotoxic potential (Fig. 4E). Although the majority of
Perf/GzmB+ pMHCII tetramer+ CD4+ T cells expressed CX3CR1
with Hobit and/or Eomes (Fig. 4E, left panel), similar combinatorial
profiles were detected among Perf/GzmB2 pMHCII tetramer+ CD4+
T cells (Fig. 4E, right panel).
Clonal evolution of EBV-specific CD4+ T cells
To determine if changes in functionality over time were associated
with changes in clonal composition, we performed a longitudinal
analysis of clonotype use among CD4+ T cell populations. We
focused our efforts on the EBNA2276–295 epitope, which can be
presented by DR7 or HLA-DRB3*02:02 (DR52b) (23), and
against which expanded populations of CD4+ T cells have been
observed during primary EBV infection (22).
Initially, we used a commercially available Ab kit to examine
TCRVb expression on the surface of DR7/EBNA2276–295–specific
FIGURE 2. Acute IM drives expanded populations of polyfunctional EBV-specific CD4+ T cells. (A–C) CD4-enriched PBMCs from patients with IM and
healthy carriers were stained with the relevant pMHCII tetramers (Table I) (A) and analyzed for surface expression of CD38 (n = 13 for acute IM and n = 6
for healthy carriers[HC]) (B) and intracellular expression of T-bet and FoxP3 in patients with IM (n = 4) (C) by flow cytometry. Blue, total CD4+ T cells;
red, EBV-specific pMHCII tetramer+ CD4+ T cells. (D–F) PBMCs from patients with IM and HC were either unmanipulated (unfilled) or stimulated with
autologous LCLs (filled) and analyzed by flow cytometry for intracellular expression of IFN-g, TNF-a, and IL-2 (D and E) and surface mobilization of
CD107a (F). The summary graphs (D and F) depict results from eight independent experiments with a minimum of four donors. (E) SPICE plots illustrating
the functional profiles of CD4+ T cells from patients with IM and HC responding to autologous LCLs. Image sizes are scaled to depict the overall numbers
of responding cells. Each pie chart segment displays the fraction of responding cells producing the number of cytokines indicated in the key. Arcs show the
distribution of each individual function. Error bars indicate means 6 SD. Significance was determined by unpaired Student t test with Welch correction
(b and c) or the Mann–Whitney U test (f). ***p , 0.001, ****p , 0.0001.
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+ T cells. Successful dual
staining of epitope-specific CD4+ T cell clones of known TCRVb
usage showed that there was no detectable competition be-
tween Vb-specific Abs and pMHCII tetramers for the TCR
(Supplemental Fig. 3). Representative clonograms for DR7/
EBNA2276–295–specific (donor IM273) and DR52b/EBNA2276–295–
specific CD4+ T cells (donor IM201) are shown in Fig. 5A, anno-
tated using the nomenclature of Wei et al. (45). In each of these
patients with IM, the expressed TCR Vb repertoire differed mark-
edly between the EBV-specific CD4+ T cell population and the total
CD4+ T cell pool. Repertoire bias was also observed in the EBV-
specific CD4+ T cell populations. In donor IM273, 24.5% of DR7/
EBNA2276–295–specific CD4
+ T cells expressed Vb3 compared
with only 1.3% of the total CD4+ T cell pool, whereas in donor
IM201, 16.2% of DR52b/EBNA2276–295–specific CD4
+ T cells
expressed Vb21.3 compared with only 2.4% of the total CD4+
T cell pool. In contrast, the corresponding EBV-specific CD4+
T cell repertoire profiles in healthy carriers were more evenly
distributed overall and incorporated only modest Vb-defined ex-
pansions (Fig. 5B).
Subsequently, we used an unbiased molecular approach to
characterize all expressed TRB gene rearrangements in EBV-
specific CD4+ T cell populations (31). Data were annotated us-
ing the International ImMunoGeneTics nomenclature (33). We
first compared the repertoires of DR7/EBNA2276–295–specific
CD4+ T cells in two patients with IM (donor IM260 and donor
IM265). In accordance with the Vb expression data (Fig. 5A),
preferential TRBV gene use was apparent in both of these EBV-
specific CD4+ T cell populations (Fig. 6, top panel). The DR7/
EBNA2276–295–specific CD4
+ T cell population in donor IM260
favored TRBV20-1 (39%), whereas the DR7/EBNA2276–295–
specific CD4+ T cell population in donor IM265 favored
TRBV12-3 (68%). A single dominant clonotype was responsible
for the observed TRBV gene bias in each case. We then performed
similar analyses using serial samples collected from the same
donors at 2–3 wk and.18 mo after diagnosis. There was a progressive
FIGURE 3. EBV-specific CD4+ T cells express cytotoxic proteins in patients with IM. (A–G) CD4-enriched PBMCs from healthy carriers (HC), patients
with acute IM and patients with convalescent IM were stained with the relevant pMHCII tetramers (Table I) and analyzed by flow cytometry for intra-
cellular expression of Perf/GzmB. (A) Perf/GzmB expression in the total CD4+ T cell pool shown for two representative HC. (B) Representative DR7/
EBNA2276–295 and DR7/M143–59 tetramer stains (top panels) and Perf/GzmB expression among pMHCII tetramer
+ CD4+ T cells (bottom panels) shown for
a DR7+ HC. (C) Perf/GzmB expression in the total CD4+ T cell pool shown for a representative patient with acute IM. (D) Representative DR7/EBNA2276–295
and DR7/M143–59 tetramer stains (top panels) and Perf/GzmB expression among pMHCII tetramer
+ CD4+ T cells (bottom panels) shown for a DR7+ patient
with acute IM. (E) Perf/GzmB in the total CD4+ T cell pool shown for a representative patient during convalescence. (F) Representative DR7/EBNA2276–295
tetramer stain (top panels) and Perf/GzmB expression among pMHCII tetramer+ CD4+ T cells (bottom panels) shown for a DR7+ patient during conva-
lescence. (G) Summary of Perf/GzmB expression in the total CD4+ (blue) and EBV-specific pMHCII tetramer+ CD4+ T cell populations (red) from patients
with acute IM (n = 12), patients with convalescent IM (n = 5), and HC (n = 15). Error bars indicate means 6 SD. Significance was determined by unpaired
Student t test with Welch correction between total CD4+ and pMHCII+ populations and the Mann–Whitney U test for comparison between donor groups
(h). *p , 0.05, ***p , 0.001, ****p , 0.0001. NS, not significant.
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contraction of the initially dominant clonotypes in both donors
(clone 1 and clone 3 in donor IM260 and clone I in donor IM265),
and new clonotypes emerged over time, some of which became
dominant (clone 4 in donor IM260 and clone II in donor IM265).
Interestingly, a public TRBV7-9+ DR7/EBNA2276–295–specific
clonotype (*) identified during acute infection was detected at all
time points in both donors, demonstrating persistence into long-
term memory. Although identical at the amino acid level, the
corresponding CDR3b loops were differentially encoded at the
nucleotide level (Fig. 6B), in line with the principles of con-
vergent recombination (46, 47).
Expression of cytotoxic proteins in EBV-specific CD4+ T cells
is associated with activation
Given that the observations that Perf/GzmB and CX3CR1/Hobit
expression were never universal within individual pMHCII
tetramer+ CD4+ T cell populations (Fig. 3G), we assessed whether
cytotoxicity was associated with dominant Vb-defined expansions
in patients with IM. However, there were no obvious associations
between Perf/GzmB expression and TCR Vb use among DR7/
EBNA2276–295–specific CD4
+ T cells in donor IM273 or DR52b/
EBNA2276–295–specific CD4
+ T cells in donor IM201 (Fig. 7A).
Rather, Perf/GzmB expression was heterogeneous among
Vb-defined pMHCII tetramer+ CD4+ T cells and reflected that
among the total pMHCII tetramer+ CD4+ T cell population. Im-
portantly, however, these data suggest that individual clonotypes
can comprise cells with different functional capacities.
A search for other correlates of cytotoxic potential revealed that
Perf/GzmB expression was strongly associated with cellular ac-
tivation in primary EBV infection (Fig. 7B–D). Within the total
CD4+ T cell pool of donor IM243, Perf/GzmB expression was
almost exclusively limited to cells expressing high levels of
FIGURE 4. Acutely generated EBV-
specific CD4-CTLs are transcriptionally
distinct from classically defined virus-specific
CD4-CTLs. (A) Expression of CX3CR1,
NKG2D, CRTAM, Hobit, and Eomes in the
total CD4+ T cell pool from a representative
healthy carrier (HC). (B) Expression of
CX3CR1, NKG2D, CRTAM, Hobit, and
Eomes in the total CD4+ (top panels) and
DR7/EBNA2275–296 tetramer
+ CD4+ T cell
populations (bottom panels) from a repre-
sentative patient with IM. (C) Summary of
CX3CR1, NKG2D, CRTAM, Hobit, and
Eomes expression in total CD4+ (blue)
and EBV-specific pMHCII tetramer+ CD4+
T cell populations (red) from patients with
IM (n = 6). (D) Summary of CX3CR1,
Hobit, and Eomes expression in Perf/
GzmB+ (filled) and Perf/GzmB2 pMHCII
tetramer+ CD4+ T cell populations (un-
filled) from patients with IM (n = 6). (E)
SPICE plots illustrating the expression
profiles of CX3CR1, Hobit, and Eomes
among Perf/GzmB+ and Perf/GzmB2
pMHCII tetramer+ CD4+ T cells from pa-
tients with IM (n = 6). Image sizes are
scaled to depict the distribution of Perf/
GzmB+ and Perf/GzmB2 events among
pMHCII tetramer+ CD4+ T cells. Each pie
chart segment displays the fraction of cells
expressing the number of markers indicated
in the key. Arcs show the distribution of
each individual marker. (C–E) Error bars
indicate means 6 SD. Significance was
determined by unpaired Student t test with
Welch correction (c) and the Mann–Whitney
U test for (d). **p , 0.01, ***p , 0.001,
****p , 0.0001. NS, not significant.
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CD38hi (Fig. 7B, top panel). Accordingly, in the heavily expanded
pMHCII tetramer+ population, in which CD38hi was almost
ubiquitously expressed, the vast majority of cells were positive for
Perf/GzmB (Fig. 7B, bottom panel). In donor IM211, in which the
lower magnitude of the pMHCII tetramer+ population and lower
overall frequencies of Perf/GzmB+ and CD38hi events in the total
CD4+ T cell pool indicated blood donation later after disease onset
(Fig. 7C, top panel), a lower frequency of EBV-specific CD4+
T cells were Perf/GzmB+ (Fig. 7C, bottom panel). Importantly,
however, expression of cytotoxic proteins was limited to those
cells expressing CD38hi. The concatenated data from all pa-
tients with acute or convalescent IM (Fig. 7D) show a strong
correlation between the percentage frequency of Perf/GzmB+
events and the percentage frequency of CD38hi events among
both total CD4+ T cells (R2 = 0.96, p . 0.0001) and EBV-
specific pMHCII tetramer+ CD4+ T cells (R2 = 0.87, p .
0.0001). Together, these data demonstrate a clear association
between cellular activation and the cytotoxic potential of EBV-
specific CD4-CTLs.
Discussion
The global CD4+ T cell pool comprises functionally diverse
subsets characterized by the expression of distinct cytokines and
transcription factors (3). However, the clonotypic architecture and
functional properties of virus-specific CD4+ T cell populations
remain poorly defined. We addressed these issues in the context
of EBV infection, which elicits an array of cellular immune
responses (20), including Ag-specific CD4+ T cell expansions
amenable to analysis with pMHCII tetramers (22).
Using ex vivo peptide stimulation assays, we found that pMHCII
tetramer+ CD4+ T cells produced IFN-g, TNF-a, and IL-2 during
persistent infection, consistent with a TH1-like profile regulated by
T-bet (3) and also with previous in vitro studies implicating
polyfunctional CD4+ T cells in the long-term control of EBV (14,
48, 49). Importantly, effector cytokines were also produced ex
vivo in response to physiological levels of Ag presented on
the surface of virus-infected B cells. Direct MHCII-restricted
recognition of EBV-infected LCLs by CD4+ T cells has only
previously been demonstrated in vitro (23–29), always in cultured
or expanded cells. Such ex vivo reactivity in the absence of prior
activation is an important indicator of direct effector functionality
in vivo. Of note, LCL stimulation induced fewer functions per cell
than peptide stimulation, potentially reflecting differences in cy-
tokine production among epitope specificities within the broadly
targeted CD4+ T cell response (20, 50, 51) and/or the delivery of a
weaker antigenic stimulus (52). Nevertheless, in both settings, the
cytokine response was dominated by TNF-a in healthy carriers, as
reported for CD4+ T cells targeting viral epitopes in persistent
CMV or HIV infection (40, 43).
During primary EBV infection, significantly greater percentages
of circulating CD4+ T cells responded directly to ex vivo LCL
stimulation. However, the responding cells in patients with IM
typically produced fewer cytokines than LCL-responsive cells in
healthy carriers, and the overall profile was dominated by IFN-g.
Increases in polyfunctionality in CD4+ T cells over time have
similarly been observed during persistent CMV infection (53) and
during primary EBV infection in children (14), potentially reflecting
progressive differentiation and/or preferential selection of cognate
CD4+ T cells bearing high-affinity TCRs (52, 53).
Ex vivo LCL challenge also induced degranulation among CD4+
T cells in patients with IM. Classically, human CD4-CTLs have
been described in vivo almost exclusively in the setting of per-
sistent viral infections, including CMV, dengue virus, and HIV
(17, 43, 54). With regard to EBV, cytotoxic function in CD4+
T cells derived from healthy carriers has been reported but always
following in vitro culture and expansion (24–26, 28). Surprisingly,
upon ex vivo analysis, we found very little evidence of EBV-
specific CD4-CTLs in healthy carriers. Rather, cytotoxic activity
was limited almost exclusively to EBV-specific CD4+ T cells in
patients with IM. Accordingly, most pMHCII tetramer+ CD4+
T cells expressed Perf/GzmB during acute infection, whereas very
few pMHCII tetramer+ CD4+ T cells expressed Perf/GzmB during
persistent infection. Moreover, we found that Perf/GzmB expres-
sion was significantly elevated in the total CD4+ T cell pool during
FIGURE 5. EBV-specific CD4+ T cells
display biased TCR Vb use in patients with
IM. (A and B) CD4-enriched PBMCs from
patients with IM (A) and healthy carriers
(HC) (B) were stained with the indicated
pMHCII tetramers and analyzed by flow
cytometry for surface expression of defined
TCR Vb segments. Clonograms show the
distribution of specific TCR Vb segments
among total CD4+ (blue) and EBV-specific
pMHCII tetramer+ CD4+ T cells (red). The
dominant TCR Vb segment is highlighted
in each case.
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acute EBV infection, consistent with previous indications of raised
Perf in CD4+ T cells at this time (19). Given the absence of by-
stander activation among coexistent influenza virus–specific CD4+
T cell populations, which has been reported previously in the
context of viral or vaccine challenge (55–57), this observation
suggests that the cumulative effect of broadly targeted EBV-
specific CD4+ T cell responses is sufficient to impact the to-
tal CD4+ T cell pool (22). Interestingly, in the convalescent
phase, Perf/GzmB expression remained elevated among pMHCII
tetramer+ CD4+ T cells compared with the corresponding speci-
ficities in healthy carriers. This potentially reflects continued Ag
exposure because ongoing lytic replication is known to persist in
the throat for many months following primary infection (58, 59).
The subsequent establishment of viral latency may limit antigenic
drive in long-term persistent infection, which, in turn, may explain
the relative lack of Perf/GzmB expression among EBV-specific
CD4+ T cells in healthy carriers. Furthermore, differences in the
differentiation status of CD4+ T cells specific for different viruses
may impact their functional profiles during persistent infection.
Thus, EBV-specific memory CD4+ T cells typically occupy the
earlier-differentiated TCM and TEM pools (22, 60), contrasting
with later-differentiated TEMRA cells predominantly seen in other
persistent viral infections in which CD4-CTLs are commonly seen
(17, 40, 43). Accordingly, acquisition of Perf/GzmB–mediated
cytotoxicity among memory CD4+ T cells has been shown to
increase with progressive differentiation (4, 53), as observed
during persistent CMV and HIV infection (19, 43).
Several cellular markers have been associated with the devel-
opment and/or function of CD4-CTLs in the setting of persistent
viral infection or cancer (11, 17, 40, 41, 43). Of these, the tran-
scription factors Eomes, which is associated with cytotoxicity
programs in CD8+ T cells (61), and Hobit, which is associated
with tissue residency (62, 63), as well as the fractalkine receptor
CX3CR1, which is involved in the adhesion and trafficking
of lymphocytes (64), were all raised among Perf/GzmB+ pMHCII
tetramer+ CD4+ T cells in patients with IM. However, no indi-
vidual marker or combination of markers defined all Perf/GzmB+
EBV-specific CD4+ T cells. Although the correlation with Perf/
GzmB expression may be prone to underestimation because of the
prior release of cytotoxic molecules in vivo during ongoing in-
fection, ∼5% of Perf/GzmB+ pMHCII tetramer+ CD4+ T cells
lacked expression of Eomes, Hobit, and CX3CR1. Together,
these data suggest that EBV-specific CD4-CTLs elicited by pri-
mary EBV infection are transcriptionally distinct from classical
CD4-CTLs described in persistent viral infection. Thus, another
pathway must drive their Perf/GzmB expression, potentially
involving other transcription factors and/or regulatory pro-
teins (4, 65, 66).
We next investigated whether cytotoxic capacity in EBV-specific
CD4+ T cells in primary EBV infection was associated with
FIGURE 6. Primary EBV infection induces oligoclonal
expansions of Ag-specific CD4+ T cells. (A) Serial analysis
of expressed TRB gene transcripts in EBV-specific CD4+ T
cell populations from patients with IM. Each pie chart
segment denotes a unique clonotype. Dominant clonotypes
are indicated as 1–4 in donor IM260, and I and II in donor
IM265. A public sequence is indicated with an asterisk. (B)
Nucleotide sequences encoding the public amino acid
sequence.
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dominant Vb-defined expansions. Oligoclonal expansions of EBV-
specific CD8+ T cells, but not EBV-specific CD4+ T cells, have
been detected previously in the setting of IM (67, 68). However,
these early studies were restricted to low-definition technologies
in total CD4+ T cell pools. In this study, using pMHCII tetramers,
we found marked preferences for certain TCR Vb-chains among
EBV epitope-specific CD4+ T cell populations, which reflected
dramatic expansions of highly dominant clonotypes in patients
FIGURE 7. Expression of cytotoxic proteins in EBV-specific CD4+ T cells is associated with cellular activation. (A) Perf/GzmB expression among total
pMHCII tetramer+ CD4+ (left plots) and dominant TCR Vb+ pMHCII tetramer+ CD4+ T cells (right plots) from the donors shown in Fig. 5A. (B and C)
CD4-enriched PBMCs from two representative patients with IM were stained with the relevant pMHCII tetramers (left plots) and analyzed by flow
cytometry for expression of Perf/GzmB and CD38 (right plots) in the total CD4+ (top panels) and pMHCII tetramer+ CD4+ T cell populations (bottom
panels). (D) Correlation between Perf/GzmB expression and CD38hi events among total CD4+ (left plot, p , 0.0001) and pMHCII tetramer+ CD4+ T cell
populations (right plot, p , 0.0001) from patients with acute and convalescent IM. Significance was determined using the Pearson correlation.
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with IM. In addition, distinct TRBV biases within the same Ag
specificities were noted across individuals, and a public clonotype
was detected at low frequency, in line with previous studies of
EBV epitope-specific CD8+ T cells (69). Moreover, the dominant
clonotypes persisted into convalescence, albeit with a degree
of contraction, indicating selection into the memory pool (70).
Newly recruited clonotypes also emerged over time, as reported
previously for epitope-specific CD8+ T cell populations in CMV
infection (71). Of note, preferential use of TRBV7-9 among DR7/
EBNA2276–295–specific CD4
+ T cells was observed at all time
points across individuals, suggesting an important germline-encoded
contribution to Ag recognition (72, 73).
Importantly, there was no evidence to suggest preferential ex-
pression of Perf/GzmB among Vb-defined pMHCII tetramer+
CD4+ T cells in patients with IM. This observation aligns with a
similar lack of association between TCR use and function among
CMV-specific CD4+ T cells (53) and suggests that individual
clonotypes can exist in different functional states (70). Instead, we
found a strong correlation between Perf/GzmB expression and
cellular activation, defined using the surrogate marker CD38. The
association of activation and cytotoxic capacity held true in con-
valescence, in which only those EBV-specific CD4+ T cells that
remained activated expressed Perf/GzmB. High levels of activated
pMHCII tetramer+ CD4+ T cells during primary EBV infection is
consistent with previous reports of increased CD38 expression in
CD4+ T cells in primary HIV infection and following vaccinia
virus vaccination (15, 74). However, it is yet unknown if the ac-
tivated CD4+ T cells induced in these settings express Perf/GzmB;
a recent report of GzmB transcripts in virus-specific CD4+ T cells
elicited during primary CMV infection suggests that this warrants
further investigation (11). The acute wave of activated EBV-
specific CD4-CTLs in primary infection markedly contrasts with
classically reported CD4-CTLs, which have long been considered
a feature of viral persistence and terminal differentiation in the
setting of other viral infections (4, 17, 40, 43). How the acutely
generated EBV-specific CD4-CTLs are regulated at the tran-
scriptional level in relation to chronically maintained CD4-CTLs
remains to be determined.
The lack of ex vivo cytotoxic potential among EBV-specific
memory CD4+ T cells contrasts with in vitro studies, which have
shown that EBV-specific CD4+ T cell lines and clones derived from
healthy carriers almost invariably express Perf/GzmB and exhibit
direct cytotoxicity against EBV-infected B cells (23–26, 28, 29).
Acquisition of cytotoxic functions during in vitro stimulation and
culture does not appear to result from progressive cellular differ-
entiation because EBV-specific CD4+ T cell clones retain an ef-
fector CCR72CD45RA2 phenotype (24). It therefore seems likely
that Perf/GzmB expression can be induced in EBV-specific memory
CD4+ T cells upon Ag encounter, consistent with an intimate as-
sociation between activation and cytotoxicity in the CD4+ T cell
lineage. However, possible rapid expansion of a small minority of
high-affinity Perf/GzmB+ memory CD4+ T cells that are retained in
healthy carriers cannot be discounted.
In summary, we have shown that primary EBV infection elicits
oligoclonal populations of highly activated and directly cytotoxic
virus-specific CD4+ T cells with a TH1-like functional profile that
respond immediately to ex vivo challenge with autologous LCLs.
These findings suggest that activated CD4-CTLs have the poten-
tial to eliminate virus-transformed B cells in vivo, potentially
informing the rational development of novel vaccines designed to
combat EBV-associated diseases.
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